142 related articles for article (PubMed ID: 28266766)
21. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
22. Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.
Woehlecke C; Wittig S; Sanft J; Kreyenberg H; Gruhn B
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1283-90. PubMed ID: 25617314
[TBL] [Abstract][Full Text] [Related]
23. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.
Hoffmann JC; Stabla K; Burchert A; Volkmann T; Bornhäuser M; Thiede C; Neubauer A; Brendel C
Ann Hematol; 2014 Feb; 93(2):279-85. PubMed ID: 24352219
[TBL] [Abstract][Full Text] [Related]
25. Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia.
Haugaard AK; Madsen HO; Marquart HV; Rosthøj S; Masmas TN; Heilmann C; Müller KG; Ifversen M
Pediatr Transplant; 2019 Nov; 23(7):e13549. PubMed ID: 31313439
[TBL] [Abstract][Full Text] [Related]
26. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
Eefting M; de Wreede LC; Halkes CJ; von dem Borne PA; Kersting S; Marijt EW; Veelken H; Putter H; Schetelig J; Falkenburg JH
Haematologica; 2016 Apr; 101(4):506-14. PubMed ID: 26802054
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K
Bone Marrow Transplant; 2007 Dec; 40(11):1027-32. PubMed ID: 17846595
[TBL] [Abstract][Full Text] [Related]
29. Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.
Jiang Y; Wan L; Qin Y; Wang X; Yan S; Xie K; Wang C
PLoS One; 2015; 10(7):e0133671. PubMed ID: 26226104
[TBL] [Abstract][Full Text] [Related]
30. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
31. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
32. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
33. Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Tamura S; Saheki K; Takatsuka H; Wada H; Fujimori Y; Okamoto T; Takemoto Y; Hashimoto-Tamaoki T; Furuyama J; Kakishita E
Ann Hematol; 2000 Nov; 79(11):622-6. PubMed ID: 11131921
[TBL] [Abstract][Full Text] [Related]
34. The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation.
Li Z; Wang J; Deng L; Liu X; Kong F; Zhao Y; Hou Y; Zhou F
Front Immunol; 2024; 15():1382099. PubMed ID: 38665912
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
36. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
Shimomura Y; Hara M; Katoh D; Hashimoto H; Ishikawa T
Ann Hematol; 2018 Jun; 97(6):1049-1056. PubMed ID: 29455235
[TBL] [Abstract][Full Text] [Related]
37. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
38. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
39. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
Scott BL; Storer BE; Greene JE; Hackman RC; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2007 Mar; 13(3):345-54. PubMed ID: 17317588
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of hematopoietic chimerism after transplantation for pediatric myelodysplastic syndrome: real-time or conventional short tandem repeat PCR in peripheral blood or bone marrow?
Willasch AM; Kreyenberg H; Shayegi N; Rettinger E; Meyer V; Zabel M; Lang P; Kremens B; Meisel R; Strahm B; Rossig C; Gruhn B; Klingebiel T; Niemeyer CM; Bader P
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1918-25. PubMed ID: 25087899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
